THE EFFECT OF FINASTERIDE ON PROSTATE VOLUME, URINARY FLOW RATE AND SYMPTOM SCORE IN MEN WITH BENIGN PROSTATIC HYPERPLASIA

1995 ◽  
Vol 65 (1) ◽  
pp. 35-39 ◽  
Author(s):  
John N. Nacey ◽  
Patrick J. Meffan ◽  
Brett Delahunt
Keyword(s):  
Benign Prostatic Hyperplasia ◽  
Symptom Score ◽  
Flow Rate ◽  
Prostate Volume ◽  
Prostatic Hyperplasia ◽  
Urinary Flow Rate ◽  
Urinary Flow

scholarly journals Efficacy and Safety of Combine Alfuzosin and Finasteride in the Treatment of Symptomatic Benign Prostatic Hyperplasia: A Quasi-Experimental Study

2018 ◽  
Vol 16 (2) ◽  
pp. 35-39
Author(s):  
Md Saifuddin Ahmed Siddique ◽  
Sharmin Nahar Bashar ◽  
Farid Uddin Ahmed
Keyword(s):  
Experimental Study ◽  
Benign Prostatic Hyperplasia ◽  
Combination Therapy ◽  
Flow Rate ◽  
Prostate Volume ◽  
Prostatic Hyperplasia ◽  
Urinary Flow Rate ◽  
Urinary Flow ◽  
Efficacy And Safety ◽  
Quasi Experimental

Background: Lower Urinary Tract Symptoms (LUTS) due to Benign Prostatic Hyperplasia (BPH) are common in elder men and a number of drugs alone or in combination are clinically used for this disorder. To assess the efficacy and safety of combined Alfuzosin plus Finasteride, in patients with LUTS due to BHP.Methods: In this hospital-based, Quasi-experimental study (One-Group Pre test-Post test Design) without Control Groups, 30 consecutive patients were selected as per set criteria for medical management of BPH with combination of 10mg Alfuzosin and 5mg Finasteride, for 12-months, in the outpatient Department of Urology, in Chittagong Medical College Hospital. The primary efficacy criteria were improvement in symptoms (International Prostate Symptom Score (IPSS) peak urinary flow rate and reduction of prostate volume from baseline.Results: Combination therapy with Alfuzosin plus Finasteride was effective in improving the symptoms and peak urinary flow rate from the first follow-up visit (Day 90) in comparison to baseline score. The mean change in the IPSS from baseline at endpoint was 10±1.87 (p=0.001). The percentage increase in the peak urinary flow rate was 4.8 mL/s, compared with 11.0±1.82 mL/s at baseline (p=0.001). The patients’ quality of life also significantly improved. The percentage decrease in prostate volume at end point was 15.13±11.3 cc (p=0.001). Overall, this combination therapy was well tolerated. The incidence of orthostatic hypotension as determined by systematic blood pressure measurements was only 3(10%). No clinically relevant ejaculation disorders were observed.Conclusion: Alfuzosin plus Finasteride provides effective relief from the symptoms of benign prostatic hyperplasia by reducing the size of the prostate. It is well tolerated from a cardiovascular viewpoint and is not associated with abnormal ejaculation.Chatt Maa Shi Hosp Med Coll J; Vol.16 (2); July 2017; Page 35-39

scholarly journals Body Mass Index and Risk of Prostate Volume, International Prostate Symptom Score, Maximum Urinary Flow Rate, and Post-Void Residual in Benign Prostatic Hyperplasia Patients

2019 ◽  
Vol 13 (4) ◽  
pp. 155798831987038 ◽  
Author(s):  
Bing-Hui Li ◽  
Tong Deng ◽  
Qiao Huang ◽  
Hao Zi ◽  
Hong Weng ◽  
...  
Keyword(s):  
Body Mass Index ◽  
Benign Prostatic Hyperplasia ◽  
Body Mass ◽  
Flow Rate ◽  
Prostate Volume ◽  
Prostatic Hyperplasia ◽  
Urinary Flow Rate ◽  
Urinary Flow ◽  
Increased Risk ◽  
Maximum Urinary Flow

The objective of this study was to evaluate association between body mass index (BMI) and prostate volume (PV), international prostate symptom scores (IPSS), maximum urinary flow rate ( Qmax), and post-void residual (PVR) of Chinese benign prostatic hyperplasia (BPH) patients. All newly diagnosed BPH patients between September 2016 and August 2018 were selected and 788 patients were included. According to BMI, the patients were categorized into four groups, while according to PV, IPSS, Qmax, and PVR, they were categorized into two groups based on clinical significant cutoffs. Univariable and multivariable logistic regressions and a restricted cubic spline (RCS) were applied to explore the relationship of BMI with categorical PV, IPSS, Qmax, and PVR. Compared with normal BMI, obesity presented significant association with increased risk of larger PV (>80 ml) in both unadjusted and adjusted models (unadjusted odds ratio [OR] = 1.772, 95% CI [1.201, 2.614], p = .004; adjusted OR = 1.912, 95% CI [1.212, 3.017], p = .005); however, underweight or overweight did not present a significant connection with such risk. No significant effect was identified for BMI on IPSS, Qmax, or PVR in either unadjusted or adjusted model. Nonlinear test including BMI using RCS and adjusting for confounders showed no significance ( p > .05); however, a significant linear relationship was ascertained between BMI and the risk of larger PV ( p < .001). In conclusion, there was a significant linear association between BMI and the risk of larger PV in BPH patients. Hence, this suggests urologists should consider both BMI and PV when providing surgical treatment for BPH patients.

Relationship among symptom score, prostate volume, and urinary flow rates in 543 patients with and without benign prostatic hyperplasia

The Prostate ◽  
1998 ◽  
Vol 34 (2) ◽  
pp. 121-128 ◽  
Author(s):  
Alessandro Sciarra ◽  
Giuseppe D'Eramo ◽  
Paolo Casale ◽  
Andrea Loreto ◽  
Maurizio Buscarini ◽  
...  
Keyword(s):  
Benign Prostatic Hyperplasia ◽  
Symptom Score ◽  
Prostate Volume ◽  
Prostatic Hyperplasia ◽  
Urinary Flow ◽  
Flow Rates

scholarly journals Clinical Significance of Intravesical Prostatic Protrusion in Patients with Benign Prostatic Hyperplasia

2015 ◽  
Vol 3 (1) ◽  
pp. 6-10 ◽  
Author(s):  
Ghanshyam Sigdel ◽  
WK Belokar
Keyword(s):  
Benign Prostatic Hyperplasia ◽  
Symptom Score ◽  
Flow Rate ◽  
International Prostate Symptom Score ◽  
Prostate Volume ◽  
Maximum Flow ◽  
Prostatic Hyperplasia ◽  
Medical Sciences ◽  
Residual Urine ◽  
Intravesical Prostatic Protrusion

INTRODUCTION: Intravesical prostatic protrusion is a morphological change due to excessive growth of the median and lateral lobes of the prostate into the bladder in benign prostatic hyperplasia. It causes a 'ball-valve' type of obstruction during voiding. It is a useful parameter to assess the severity of the disease process, selection of treatment modality and its possible outcome in benign prostatic hyperplasia.MATERIAL AND METHODS: A prospective, non-randomized, observational study was carried out from January 2014 to June 2014 in the Department of Urology, College of Medical Sciences, Nepal. Total of 50 patients with benign prostatic hyperplasia were evaluated to assess the correlation of intravesical prostatic protrusion with international prostate symptom score, prostate volume, maximum flow rate and post void residual urine. Correlation between parameters of interest was quantified with Pearson correlation test.RESULTS: A positive correlation was demonstrated between intravesical prostatic protrusion, international prostate symptom score, prostate volume and post void residual urine. There was a negative correlation between intravesical prostatic protrusion and maximum flow rate.CONCLUSION: Intravesical prostatic protrusion is correlated with international prostate symptom score, prostate volume, maximum flow rate, and post void residual urine volume and hence can be used to assess the severity of benign prostatic hyperplasia.Journal of Universal College of Medical Sciences Vol. 3, No. 1, 2015: 6-10

scholarly journals The Effect of Different Metabolic Syndrome

2016 ◽  
Vol 11 (1) ◽  
pp. 158-163 ◽  
Author(s):  
Orhan Ünal Zorba ◽  
Hakkı Uzun ◽  
Görkem Akça ◽  
Selim Yazar
Keyword(s):  
Metabolic Syndrome ◽  
Symptom Score ◽  
Flow Rate ◽  
International Prostate Symptom Score ◽  
Prostate Volume ◽  
Specific Antigen ◽  
Urinary Flow Rate ◽  
Urinary Flow ◽  
Significant Difference ◽  
Maximum Urinary Flow

Because various criteria are used to define metabolic syndrome (MetS), this study examines the most relevant definition for patients with benign prostatic enlargement (BPE). Most studies regarding the link between MetS and BPE/lower urinary tract symptoms (LUTS) have used the National Cholesterol Education Program Adult Treatment Panel III criteria for diagnosis, while a few have used criteria from the International Diabetes Federation and/or American Heart Association. Patients with LUTS due to BPE are classified as having MetS or not by the aforementioned three definitions. Prostate volume, International Prostate Symptom Score, storage and voiding subscores, maximum urinary flow rate, and the postvoid urine of patients with and without MetS were compared separately in the three different groups. Surgical and medical treatment prevalence was also compared between three groups. No matter which definition was used, the International Prostate Symptom Score, the storage and voiding symptom scores, prostate volume, prostate-specific antigen, and postvoid urine were significantly higher in the patients with MetS. The maximum urinary flow rate was similar between patients with and without MetS, according to all three different definitions. There was no significant difference in the aforementioned parameter between patients with MetS diagnosed with the three different definitions. Irrespective of which definition was used, the surgical treatment rate was not significantly different in patients diagnosed with than without MetS, or between the patients with MetS diagnosed with the three different definitions. The authors suggest that it does not matter which of the aforementioned three definitions is used during the evaluation of MetS in men with BPE/LUTS.

Sign in / Sign up

Export Citation Format

Share Document